[HTML][HTML] Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes—A Review of the Literature

F Martora, N Tommasino, C Brescia, L Potestio… - Medicina, 2024 - mdpi.com
The management of hidradenitis suppurativa (HS) in elderly patients presents unique
challenges due to its chronic inflammatory nature, heterogeneous clinical presentation and …

Report of successful treatment of follicular occlusion triad with adalimumab and research progress on biologic therapy for follicular occlusion triad

R Jia, Q Diao, Y Wang - Journal of Dermatological Treatment, 2024 - Taylor & Francis
Purpose: This article aims to present a case report of a patient with Follicular occlusion triad
(FOT) who achieved successful disease control with adalimumab combined with isotretinoin …

[HTML][HTML] Association between Inflammatory Markers and Psychometric Scores in Patients with Hidradenitis Suppurativa

AI Liakou, N Rotsiamis, AG Tsantes, E Routsi… - Journal of Clinical …, 2024 - mdpi.com
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder with a
significant impact on the quality of life of affected patients. This study aimed to correlate …

[HTML][HTML] Factors Affecting Wound Healing after the Wide Surgical Excision of Hidradenitis Suppurativa Lesions

AC Ezanno, G Texier, J Marchi… - Journal of Clinical …, 2024 - mdpi.com
Background: Hidradenitis suppurativa (HS) is a chronic and inflammatory disease. Its
management depends on the stage and extent of the disease. Surgery plays an important …

Patients-oriented treatments for chronic inflammatory skin diseases

L Mastorino, S Ribero, M Burlando… - Frontiers in …, 2024 - frontiersin.org
The therapeutic options for the treatment of inflammatory skin conditions, namely psoriasis
disease, atopic dermatitis (AD), and hidradenitis suppurativa (HS), have increased …

Anti‐IL17 Secukinumab in hidradenitis suppurativa: A long‐term drug survival analysis

G Roccuzzo, F Repetto, S Giordano… - Experimental …, 2024 - Wiley Online Library
Real‐world data on the long‐term effectiveness of the anti‐IL17 agent secukinumab in
treating moderate‐to‐severe Hidradenitis suppurativa (HS) are lacking. In this study, 24 …

[引用][C] Aktuelle Empfehlungen zur Therapie der Hidradenitis suppurativa

C Kromer, H Stanisz‐Bogeski - JDDG: Journal der Deutschen …, 2024 - Wiley Online Library